Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex.
about
Physical and functional interactions between type I transforming growth factor beta receptors and Balpha, a WD-40 repeat subunit of phosphatase 2A.Binding of tumor necrosis factor alpha to activated forms of human plasma alpha 2 macroglobulinAn alpha 2-macroglobulin receptor-dependent mechanism for the plasma clearance of transforming growth factor-beta 1 in miceHeparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells.Interaction of monocytes with cocultures of human aortic wall cells involves interleukins 1 and 6 with marked increases in connexin43 message.Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques.Evidence for an age-related dysfunction in the antiproliferative response to transforming growth factor-beta in vascular smooth muscle cellsQuantification of active and total transforming growth factor-β levels in serum and solid organ tissues by bioassayCharacterization of [3H]-heparin binding in human vascular smooth muscle cells and its relationship to the inhibition of DNA synthesis.Proteoglycans in cell regulation.The extracellular regulation of growth factor actionFluid shear stress induces endothelial transforming growth factor beta-1 transcription and production. Modulation by potassium channel blockade.Activation of rat liver perisinusoidal lipocytes by transforming growth factors derived from myofibroblastlike cells. A potential mechanism of self perpetuation in liver fibrogenesis.Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II.Sustained inhibition of intimal thickening. In vitro and in vivo effects of polymeric beta-cyclodextrin sulfate.Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1.Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution.Neutralizing antibodies against transforming growth factor beta potentiate the proliferation of Ki-1 positive lymphoma cells. Further evidence for negative autocrine regulation by transforming growth factor beta.Smooth Muscle Stiffness Sensitivity is Driven by Soluble and Insoluble ECM ChemistryTransforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblastsThiol-ene and photo-cleavage chemistry for controlled presentation of biomolecules in hydrogelsVEGF-A165 potently induces human blood-nerve barrier endothelial cell proliferation, angiogenesis, and wound healing in vitro.Heparin and related drugs: beyond anticoagulant activity.Extracellular matrix molecules and their receptors: functions in neural development.Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells.Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects.Heparan sulfate in angiogenesis: a target for therapy.Agonists and Antagonists of TGF-β Family Ligands.α2-Macroglobulins: Structure and Function.Mast cells: accessory cells which potentiate fibrosis.Molecular biology and gene transfer in atherosclerosis in the stenting era.Transforming growth factor-beta: latent forms, binding proteins and receptors.A pivotal role for TGF-beta in atherogenesis?Endothelial heparan sulfate proteoglycan. I. Inhibitory effects on smooth muscle cell proliferation.Clinical trials to prevent restenosis after percutaneous coronary revascularization.Extravasation of macromolecules and possible trapping of transforming growth factor-beta in venous ulceration.Stimulation of Superficial Zone Protein/Lubricin/PRG4 by Transforming Growth Factor-β in Superficial Zone Articular Chondrocytes and Modulation by Glycosaminoglycans.Entry and distribution of fluorescent antiproliferative heparin derivatives into rat vascular smooth muscle cells: comparison between heparin-sensitive and heparin-resistant cultures.Activated alpha 2-macroglobulin is a principal defensin-binding protein.Transforming growth factor beta decreases the rate of proliferation of rat vascular smooth muscle cells by extending the G2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase.
P2860
Q24522790-246B5B0E-2558-47BA-B16B-E8D069B268E5Q30444830-58B8D462-8054-47C8-A92F-97A3FA35A85EQ30449823-288A9DDC-0B6E-4465-A88E-0E63AE3AE5A3Q34143433-4F9BC312-DD98-49C6-8A60-E9C4311D23FBQ34189269-1151523E-5E3C-4D0E-9D33-47E2993A4191Q34196344-8598A76C-0854-4CEE-8F83-63CBA9EB6182Q34436146-C3714A1B-6399-45CC-85F9-A28922046856Q34476894-40070DAD-0CF9-498C-98A4-6394C49D9A0EQ35028855-50654FD7-2383-441D-9B27-6712381AF57EQ35452819-34CDF760-CE0A-4115-A7BC-3A385BBD4A7BQ35465713-3F9C7F59-89C6-4D3C-B279-4287A63614FAQ35554195-BD9D3E3A-B851-4760-8EF4-B828A5AEFBD9Q35595788-304F3EE0-027D-4469-B9A6-B4E248690444Q35605118-C290C10F-3A1B-474F-AB71-7FC73B6B5F59Q35767647-16BDA2D5-3E08-4617-B514-5B5AE76F9406Q35767892-46FBE550-6D8B-401D-AE2C-5E3E8A55024AQ35817740-D5AB8680-0874-4524-8A99-C548F5B0A082Q35830680-ED31684F-8BDC-4DD7-A81A-9CFE17F75E65Q36175769-E9484FEC-2E4C-41EE-A461-641164F760F2Q36232642-BBAAE734-E445-4607-9864-A1154732884BQ36307667-D025477C-0BB9-4949-B436-68D66AB8FA70Q37046010-76E6EDCA-066E-4F76-892F-C2D4B469BDCBQ37105310-D3701D88-3F80-4277-9289-AAF2DBE85F61Q37178903-7120A8B1-CC0E-4DB5-837A-34BBBC7CB295Q37374163-95710D7C-D8DB-46F3-9CF1-E32768D50C32Q37882523-B42CF248-497F-4266-8041-BBDDAF5339DCQ38154506-0CB203EB-77D9-4954-88DC-18FB8CFB1831Q38896053-36DC1A5A-0548-4924-BF45-582DCFF2F831Q40304036-C8C05256-7FC3-4B04-B749-9EF09FCD37C3Q40403511-C401B56D-6A21-4E12-9618-312D9CF21BDDQ40601689-54C48126-ECD7-40BE-A9B1-8AC8C26CFAE2Q40851998-3CC7531B-61FF-4907-8195-760F1DFCE373Q40926437-74B9A7F0-0205-4DF3-B69E-0D791A5E7BA0Q41196918-302AB527-FA53-47FC-9D08-639121BDE6C8Q41500665-2FB13D0F-705E-4E37-82A3-0EF2F7C01F97Q41665871-C3F4D39A-A6F7-4613-AA98-951EFBD86826Q41764890-85123A01-674C-402D-8255-33DFBF55449DQ41931107-F5A80A0B-D3D2-4BA5-990B-A639F22BD812Q41975642-AF26E8BD-5EDA-4A0D-A2FC-3BD8A0D92B50Q42026748-2E1D874B-251D-4401-B1E6-CC5C480D17CA
P2860
Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Transforming growth factor-bet ...... acroglobulin inactive complex.
@ast
Transforming growth factor-bet ...... acroglobulin inactive complex.
@en
type
label
Transforming growth factor-bet ...... acroglobulin inactive complex.
@ast
Transforming growth factor-bet ...... acroglobulin inactive complex.
@en
prefLabel
Transforming growth factor-bet ...... acroglobulin inactive complex.
@ast
Transforming growth factor-bet ...... acroglobulin inactive complex.
@en
P2093
P2860
P356
P1476
Transforming growth factor-bet ...... acroglobulin inactive complex.
@en
P2093
B B Weksler
C F Brayton
D J Falcone
L A Agarwal
T A McCaffrey
P2860
P304
P356
10.1083/JCB.109.1.441
P407
P577
1989-07-01T00:00:00Z